Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab: An Observational Health Data Sciences and Informatics Network Study
Cindy X Cai,Akihiko Nishimura,Mary G Bowring,Erik Westlund,Diep Tran,Jia H Ng,Paul Nagy,Michael Cook,Jody-Ann McLeggon,Scott L DuVall,Michael E Matheny,Asieh Golozar,Anna Ostropolets,Evan Minty,Priya Desai,Fan Bu,Brian Toy,Michelle Hribar,Thomas Falconer,Linying Zhang,Laurence Lawrence-Archer,Michael V Boland,Kerry Goetz,Nathan Hall,Azza Shoaibi,Jenna Reps,Anthony G Sena,Clair Blacketer,Joel Swerdel,Kenar D Jhaveri,Edward Lee,Zachary Gilbert,Scott L Zeger,Deidra C Crews,Marc A Suchard,George Hripcsak,Patrick B Ryan
DOI: https://doi.org/10.1016/j.oret.2024.03.014
Abstract:Purpose: To characterize the incidence of kidney failure associated with intravitreal anti-VEGF exposure; and compare the risk of kidney failure in patients treated with ranibizumab, aflibercept, or bevacizumab. Design: Retrospective cohort study across 12 databases in the Observational Health Data Sciences and Informatics (OHDSI) network. Subjects: Subjects aged ≥ 18 years with ≥ 3 monthly intravitreal anti-VEGF medications for a blinding disease (diabetic retinopathy, diabetic macular edema, exudative age-related macular degeneration, or retinal vein occlusion). Methods: The standardized incidence proportions and rates of kidney failure while on treatment with anti-VEGF were calculated. For each comparison (e.g., aflibercept versus ranibizumab), patients from each group were matched 1:1 using propensity scores. Cox proportional hazards models were used to estimate the risk of kidney failure while on treatment. A random effects meta-analysis was performed to combine each database's hazard ratio (HR) estimate into a single network-wide estimate. Main outcome measures: Incidence of kidney failure while on anti-VEGF treatment, and time from cohort entry to kidney failure. Results: Of the 6.1 million patients with blinding diseases, 37 189 who received ranibizumab, 39 447 aflibercept, and 163 611 bevacizumab were included; the total treatment exposure time was 161 724 person-years. The average standardized incidence proportion of kidney failure was 678 per 100 000 persons (range, 0-2389), and incidence rate 742 per 100 000 person-years (range, 0-2661). The meta-analysis HR of kidney failure comparing aflibercept with ranibizumab was 1.01 (95% confidence interval [CI], 0.70-1.47; P = 0.45), ranibizumab with bevacizumab 0.95 (95% CI, 0.68-1.32; P = 0.62), and aflibercept with bevacizumab 0.95 (95% CI, 0.65-1.39; P = 0.60). Conclusions: There was no substantially different relative risk of kidney failure between those who received ranibizumab, bevacizumab, or aflibercept. Practicing ophthalmologists and nephrologists should be aware of the risk of kidney failure among patients receiving intravitreal anti-VEGF medications and that there is little empirical evidence to preferentially choose among the specific intravitreal anti-VEGF agents. Financial disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.